These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 27234592

  • 1. Effects of vancomycin versus nafcillin in enhancing killing of methicillin-susceptible Staphylococcus aureus causing bacteremia by human cathelicidin LL-37.
    Le J, Dam Q, Schweizer M, Thienphrapa W, Nizet V, Sakoulas G.
    Eur J Clin Microbiol Infect Dis; 2016 Sep; 35(9):1441-7. PubMed ID: 27234592
    [Abstract] [Full Text] [Related]

  • 2. Nafcillin enhances innate immune-mediated killing of methicillin-resistant Staphylococcus aureus.
    Sakoulas G, Okumura CY, Thienphrapa W, Olson J, Nonejuie P, Dam Q, Dhand A, Pogliano J, Yeaman MR, Hensler ME, Bayer AS, Nizet V.
    J Mol Med (Berl); 2014 Feb; 92(2):139-49. PubMed ID: 24297496
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Human cathelicidin LL-37 resistance and increased daptomycin MIC in methicillin-resistant Staphylococcus aureus strain USA600 (ST45) are associated with increased mortality in a hospital setting.
    Sakoulas G, Guram K, Reyes K, Nizet V, Zervos M.
    J Clin Microbiol; 2014 Jun; 52(6):2172-4. PubMed ID: 24648548
    [Abstract] [Full Text] [Related]

  • 7. Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus.
    Pillai SK, Wennersten C, Venkataraman L, Eliopoulos GM, Moellering RC, Karchmer AW.
    Clin Infect Dis; 2009 Oct 15; 49(8):1169-74. PubMed ID: 19769538
    [Abstract] [Full Text] [Related]

  • 8. Increased resistance to cationic antimicrobial peptide LL-37 in methicillin-resistant strains of Staphylococcus aureus.
    Ouhara K, Komatsuzawa H, Kawai T, Nishi H, Fujiwara T, Fujiue Y, Kuwabara M, Sayama K, Hashimoto K, Sugai M.
    J Antimicrob Chemother; 2008 Jun 15; 61(6):1266-9. PubMed ID: 18367458
    [Abstract] [Full Text] [Related]

  • 9. Synergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
    Leonard SN.
    PLoS One; 2012 Jun 15; 7(7):e42103. PubMed ID: 22848719
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effects of sub-inhibitory concentrations of nafcillin, vancomycin, ciprofloxacin, and rifampin on biofilm formation of clinical methicillin-resistant Staphylococcus aureus.
    Park K-H, Kim D, Jung M, Kim DY, Lee Y-M, Lee MS, Hong K-W, Bae I-G, Hong SI, Cho O-H.
    Microbiol Spectr; 2024 Jun 04; 12(6):e0341223. PubMed ID: 38651875
    [Abstract] [Full Text] [Related]

  • 12. Comparative activities of telavancin combined with nafcillin, imipenem, and gentamicin against Staphylococcus aureus.
    Leonard SN, Supple ME, Gandhi RG, Patel MD.
    Antimicrob Agents Chemother; 2013 Jun 04; 57(6):2678-83. PubMed ID: 23545527
    [Abstract] [Full Text] [Related]

  • 13. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG, Voth D, Nichol K, Karlowsky JA, Noreddin AM, Hoban DJ.
    J Antimicrob Chemother; 2009 Aug 04; 64(2):364-9. PubMed ID: 19454524
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pharmacodynamic profile of commonly utilised parenteral therapies against meticillin-susceptible and meticillin-resistant Staphylococcus aureus collected from US hospitals.
    Housman ST, Sutherland CA, Nicolau DP.
    Int J Antimicrob Agents; 2014 Sep 04; 44(3):235-41. PubMed ID: 25052866
    [Abstract] [Full Text] [Related]

  • 17. Vancomycin MICs and risk of complicated bacteremia by glycopeptide-susceptible Staphylococcus aureus.
    Falcón R, Mateo E, Oltra R, Giménez E, Albert E, Torres I, Navarro D.
    Eur J Clin Microbiol Infect Dis; 2019 May 04; 38(5):903-912. PubMed ID: 30729396
    [Abstract] [Full Text] [Related]

  • 18. Reduced susceptibility to host-defense cationic peptides and daptomycin coemerge in methicillin-resistant Staphylococcus aureus from daptomycin-naive bacteremic patients.
    Mishra NN, Bayer AS, Moise PA, Yeaman MR, Sakoulas G.
    J Infect Dis; 2012 Oct 04; 206(8):1160-7. PubMed ID: 22904338
    [Abstract] [Full Text] [Related]

  • 19. Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria.
    Mortin LI, Li T, Van Praagh AD, Zhang S, Zhang XX, Alder JD.
    Antimicrob Agents Chemother; 2007 May 04; 51(5):1787-94. PubMed ID: 17307984
    [Abstract] [Full Text] [Related]

  • 20. Comparative in vitro activity of oritavancin and other agents against methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
    Sweeney D, Shinabarger DL, Arhin FF, Belley A, Moeck G, Pillar CM.
    Diagn Microbiol Infect Dis; 2017 Feb 04; 87(2):121-128. PubMed ID: 27890418
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.